Familial Isolated Hyperparathyroidism (FIHP) Cell Models for Research

Familial isolated hyperparathyroidism (FIHP) is a rare hereditary disorder characterized by primary hyperparathyroidism (PHPT) without other syndromic features. The exact prevalence is unknown, but it accounts for approximately 1-5% of all PHPT cases (source: NCI). PHPT itself affects about 1 in 1,000 adults, with a female-to-male ratio of 3:1, and incidence increases with age (WHO). The clinical impact includes hypercalcemia, nephrolithiasis, osteoporosis, and neurocognitive symptoms. Parathyroid carcinoma is rare but can occur, with a 5-year survival of approximately 50% for metastatic disease (NCI SEER). FIHP is often underdiagnosed, and genetic testing is crucial for management.

FIHP is an ideal model for studying parathyroid tumorigenesis and calcium homeostasis. It involves multiple genes (MEN1, CASR, CDC73, and others) with incomplete penetrance, making it a powerful system to dissect genotype-phenotype correlations. Public datasets, such as TCGA (though limited for parathyroid), COSMIC, and ClinVar, provide mutation data. Open questions include the role of epigenetic modifications and the identification of novel causative genes. Gene-edited cell models enable functional validation of these variants, accelerating mechanistic research.

The pathogenesis of FIHP involves disruption of calcium-sensing and cell growth regulatory pathways. Key pathways include:

• • Calcium-Sensing Pathway: The CASR gene encodes a G-protein-coupled receptor that regulates PTH secretion. Loss-of-function mutations reduce sensitivity to extracellular calcium, leading to inappropriate PTH release.
• • Cell Cycle Regulation: MEN1 encodes menin, a tumor suppressor that interacts with histone methyltransferases to regulate gene transcription. Loss of menin leads to unchecked cell proliferation.
• • Wnt/β-catenin Signaling: CDC73 (parafibromin) is a component of the PAF1 complex, which regulates histone modifications and Wnt target genes. Mutations lead to constitutive Wnt signaling.
• • Apoptosis and Autophagy: Dysregulation of these processes contributes to parathyroid cell survival.

Data from TCGA and COSMIC (parathyroid carcinoma and adenoma datasets).

Deregulated networks in FIHP include:

• • Wnt/β-catenin pathway: Key nodes: β-catenin, TCF/LEF transcription factors, cyclin D1. Mutations in CDC73 lead to nuclear accumulation of β-catenin.
• • PI3K/AKT/mTOR pathway: Often activated in parathyroid tumors, promoting cell growth and survival.
• • MAPK/ERK pathway: Crosstalk with calcium signaling; aberrant activation contributes to proliferation.
• • Cell cycle checkpoints: Loss of menin and p27 disrupts G1/S transition.

Organoids derived from patient parathyroid tissue are emerging as more physiologically relevant models, allowing 3D culture and long-term expansion. They retain genetic heterogeneity and can be used for drug testing.

Animal models for FIHP include:

• • PDX (Patient-Derived Xenografts): Parathyroid tumor tissue implanted into immunodeficient mice; useful for drug efficacy studies.
• • GEMM (Genetically Engineered Mouse Models): Men1 knockout mice develop parathyroid hyperplasia and hypercalcemia, recapitulating FIHP.
• • Inducible models: CRISPR-based conditional knockouts allow temporal control of gene deletion.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mutations in FIHP-related genes. For example:

• • MEN1 knockout in immortalized parathyroid cells (e.g., BHP-1) to study loss-of-function effects.
• • CASR missense mutations (e.g., R185Q) introduced via HDR to model calcium-sensing defects.
• • CDC73 truncation to activate Wnt signaling.

These models are commercially available or can be custom-generated by CROs. Sequence-verified, clonally derived lines ensure reproducibility and accelerate research. They are essential for drug screening and functional validation.

Knockout and knock-in lines are used to validate the functional impact of FIHP-associated variants. For example, CRISPR-mediated MEN1 knockout in parathyroid cells leads to increased proliferation and altered gene expression, confirming its tumor suppressor role. Similarly, introducing a CASR mutation can recapitulate the hypercalcemia phenotype, allowing mechanistic studies.

Isogenic pairs (wild-type vs. mutant) are invaluable for drug screening. For instance, calcimimetics (e.g., cinacalcet) can be tested on CASR-mutant cells to assess efficacy. Resistance mechanisms can be studied by chronic exposure to drugs and subsequent genomic analysis.

CRISPR synthetic lethality screens can identify vulnerabilities in FIHP cells. For example, MEN1-deficient cells may be sensitive to inhibitors of specific epigenetic modifiers, revealing novel therapeutic targets and biomarkers.